Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRL201104 in Active Eosinophilic Esophagitis
NCT05084963Phase 2Completed
- Sponsor
- Revolo Biotherapeutics
- Start
- Oct 2021
- Primary completion
- Oct 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of IRL201104 in eosinophilic esophagitis (EoE), sponsored by Revolo Biotherapeutics. Started Oct 2021; status: completed.
02
Drugs
IRL201104
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT05084963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05084963.